Azul de metileno no tratamento da síndrome vasoplégica em cirurgia cardíaca. quinze anos de perguntas, respostas, dúvidas e certezas

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorEvora, Paulo Roberto Barbosa
dc.creatorRibeiro, Paulo José de Freitas
dc.creatorVicente, Vilella de Andrade
dc.creatordos Reis, Celso Luís
dc.creatorRodrigues, Alfredo José
dc.creatorMenardi, Antonio Carlos
dc.creatorAlves Jr., Lafaiete
dc.creatorEvora, Patrícia Martinez
dc.creatorBassetto, Solange
dc.date2014-05-27T11:23:55Z
dc.date2016-10-25T18:27:07Z
dc.date2014-05-27T11:23:55Z
dc.date2016-10-25T18:27:07Z
dc.date2009-07-01
dc.date.accessioned2017-04-06T01:36:25Z
dc.date.available2017-04-06T01:36:25Z
dc.identifierBrazilian Journal of Cardiovascular Surgery, v. 24, n. 3, p. 279-288, 2009.
dc.identifier0102-7638
dc.identifier1678-9741
dc.identifierhttp://hdl.handle.net/11449/71059
dc.identifierhttp://acervodigital.unesp.br/handle/11449/71059
dc.identifier10.1590/S0102-76382009000400005
dc.identifierS0102-76382009000400005
dc.identifier2-s2.0-72649091145.pdf
dc.identifier2-s2.0-72649091145
dc.identifierhttp://dx.doi.org/10.1590/S0102-76382009000400005
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/892096
dc.descriptionObjective: There is strong evidence that methylene blue (MB), an inhibitor of guanylate cyclase, is an excellent therapeutic option for vasoplegic syndrome (VS) treatment in heart surgery. The aim of this article is to review the MB's therapeutic function in the vasoplegic syndrome treatment. Methods: Fifteen years of literature review. Results: 1) Heparin and ACE inhibitors are risk factors; 2) In the recommended doses it is safe (the lethal dose is 40 mg/ kg); 3) The use of MB does not cause endothelial dysfunction; 4) The MB effect appears in cases of nitric oxide (NO) up-regulation; 5) MB is not a vasoconstrictor, by blocking of the GMPc system it releases the AMPc system, facilitating the norepinephrine vasoconstrictor effect; 6) The most used dosage is 2 mg/kg as IV bolus followed by the same continuous infusion because plasmatic concentrations strongly decays in the first 40 minutes; 7) There is a possible window of opportunity for the MB's effectiveness. Conclusions: Although there are no definitive multicentric studies, the MB used to treat heart surgery VS, at the present time, is the best, safest and cheapest option, being a Brazilian contribution for the heart surgery.
dc.languagepor
dc.relationBrazilian Journal of Cardiovascular Surgery
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCardiovascular surgical procedures
dc.subjectExtracorporeal circulation
dc.subjectMethylene blue
dc.subjectPostoperative complications
dc.subjectVascular diseases
dc.subjectVascular resistance/drug effects
dc.subjectguanylate cyclase
dc.subjectmethylene blue
dc.subjectdose response
dc.subjectdrug antagonism
dc.subjectheart surgery
dc.subjecthuman
dc.subjectvasoplegia
dc.subjectCardiac Surgical Procedures
dc.subjectDose-Response Relationship, Drug
dc.subjectGuanylate Cyclase
dc.subjectHumans
dc.subjectMethylene Blue
dc.subjectVasoplegia
dc.titleAzul de metileno no tratamento da síndrome vasoplégica em cirurgia cardíaca. quinze anos de perguntas, respostas, dúvidas e certezas
dc.typeOtro


Este ítem pertenece a la siguiente institución